Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 10648-0001-0 PCT	SERIAL NO. 09/446,109			
LIST OF I	REFEF	RENCES CITED BY APPL	P.ICART	APPLICANT David FAIRLIE, et al.				
		MAY 1 S		FILING DATE April 21, 2000		GROUP 1646 1653		
		E.		S. PATENT DOCUMENTS	_			
EXAMINER INITIAL		DOCUMENTO EMAR DATE		NAME CLASS		SUB FILING DATE IF APPROPRIATE		
	AA							
	AB				<u> </u>	<u></u>		<u> — </u>
FOREIGN PATENT DOCUMENTS								17:011
	DOCUMENT DATE		COUNTRY		TRANSLATION YES NO			
	AC							
	AD					<u> </u>		
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)								
AM	AE	S.M. VOGEN, et al., Journal of Peptide Research, Vol. 51, pps. 226-234, "NMR ANALYSIS OF A POTENT DECAPEPTIDE AGONIST OF HUMAN C5a ANAPHYLATOXIN," March 1998						
7	AF	R.M. TEMPERO, et al., Journal of Immunology, Vol. 158, pps. 1377-1382, "MOLECULAR ADJUVANT EFFECTS OF A CONFORMATIONALLY BIASED AGONIST OF HUMAN C5a ANAPHYLATOXIN," February 1997						
	AG	L. BARANYI, et al., Journal of Immunology, Vol. 157, pps. 4591-4601, "ANTISENSE HOMOLOGY BOXES IN C5a RECEPTOR AND C5a ANAPHYLATOXIN," November 1996						
	АН	R. KAWATSU, et al., Journal of Pharmacology and Experimental Therapeutics, Vol. 278, No. 1, pps. 432-440, "CONFORMATIONALLY BIASED ANALOGS OF HUMAN C5a MEDIATE CHANGES IN VASCULAR PERMEABILITY," July 1996						
	Al	Y. KANEKO, et al., Immunology, Vol. 86, pps. 149-154, "ANTAGONISTIC PEPTIDES AGAINST HUMAN ANAPHYLATOXIN C5a," September 1995						
	AJ	M. KAWAI, et al., Journal of Medicinal Chemistry, Vol. 34, No. 7, pps. 2068-2071, "IDENTIFICATION AND SYNTHESIS OF A RECEPTOR BINDING SITE OF HUMAN ANAPHYLATOXIN C5a," July 1991						
	AK	Z.D. KONEATIS, et al., Journal of Immunology, Vol. 153, pps. 4201-4205, "DEVELOPMENT OF C5a RECEPTOR ANTAGONISTS," November 1994						
	AL	S.D. SANDERDON, et al., Journal of Medicinal Chemistry, Vol. 83, No. 18, pps. 3669-3675, "DECAPEPTIDE AGONISTS OF HUMAN C5a: THE RELATIONSHIP BETWEEN CONFORMATION AND NEUTROPHIL RESPONSE," September 1995						
	АМ	A.M. FINCH, et al., Journal of Medicinal Chemistry, Vol. 40, No. 6, pps. 877-884, "BIOLOGICALLY ACTIVE CONFORMER OF THE EFFECTOR REGION OF HUMAN C5a AND MODULATORY EFFECTS OF N-TERMINAL RECEPTOR BINDING DETERMINANTS ON ACTIVITY," March 1997						
	AN	M. KAWAI, et al., Journal of Medicinal Chemistry, Vol. 35, No. 2, pps. 220-223, "STRUCTURE-FUNCTION STUDIES IN A SERIES OF CARBOXYL-TERMINAL OCTAPEPTIDE ANALOGUES OF ANAPHYLATOXIN C5a," January 1992						
	AO	G. DRAPEAU, et al., Biochemical Pharmacology, Vol. 45, No. 6, pps. 1289-1299, "SYNTHETIC C5a RECEPTOR AGONISTS," March 1993						PTOR
	AP	J.A. DeMARTINO, et al., Journal of Biological Chemistry, Vol. 270, No. 27, pps. 15966-15969, "ARGININE 206 OF THE C5a RECEPTOR IS CRITICAL FOR LIGAND RECOGNITION AND RECEPTOR ACTIVATION BY C-TERMINAL HEXAPEPTIDE ANALOGS," July 1995						
V	AQ	X. ZHANG, et al., Protein Science, Vol. 6, pps. 65-72, "SOLUTION STRUCTURE OF A UNIUE C5a SEMI-SYNTHETIC ANTAGONIST: IMPLICATIONS IN RECEPTOR BINDING," January 1997						
M	AR T.C. PELLAS, et al., Journal of Immunology, Vol. 160, pps. 5616-5621, "NOVEL C5a RECEPTOR ANTAGONISTS REGULATE NEUTROPHIL FUNCTIONS IN VITRO AND IN VIVO," June 1998							ONISTS
	AS				Τ			
Examiner Abdel A. Mohamed Date Considered 5/3/02								
*Examiner: Ini	tial if re	eference is considered, white considered is considered. Include copi	hether or not y of this form	citation is in conformance with MPEP 6 with next communication to applicant.	09; Draw l	ne through	citation	if not in

PREMINITION TO APPLICANT.

MAY 222 150029900